Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Decision Making in the Era of Individualized Treatment in

Advanced NSCLC:Highlights From Chicago

Third-Generation EGFR TKIs

EGFR Inhibitors Following Progression on EGFR-Directed

TherapyPreliminary Efficacy Comparison

Antiangiogenic Agents in Advanced NSCLC

First-line Therapy in Advanced NSCLC

Targeting MET in Advanced NSCLC

Global Phase 3 Trial (METLung)* of Onartuzumab

Plus Erlotinib in NSCLC Trial Design

METLung TrialOverall Survival Results

Crizotinib in Advanced MET-amplified NSCLC

Patient Eligibility: NSCLC MET Amplification Cohort

Characteristics of Patients With ALK-Positive Disease; Second- Generation ALK

Inhibitors

ASCEND-1 Trial: Ceritinib in ALK-Positive Advanced NSCLC

Best Percentage Change From Baseline

Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)